Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ in Patients with Leptomeningeal Metastases (GlobeNewswire) - Jul 15, 2025 - "Plus Therapeutics...announces the oral presentation of its ReSPECT-LM clinical trial results and a sponsored educational symposium, at the upcoming SNO/ASCO CNS Metastases Conference on August 14-16, 2025....'At SNO/ASCO this year, our objective is to present the final clinical trial results and proposed clinical development path forward to clinical leaders in Neuro-oncology and further discuss this in our sponsored symposium'....Plus will also host an educational symposium with leading experts titled, 'Reimagining Your Approach to Leptomeningeal Metastases'....The session will focus on the latest advancements in understanding and managing LM, including a deep dive into REYOBIQ and CNSide and their potential roles in both prolonging life and improving the quality of life in patients with LM."
Clinical data • Brain Cancer • CNS Tumor
|